NCT02145715View on ClinicalTrials.gov

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

January 31, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Velcade

DRUG

Thalidomide

DRUG

Dexamethasone

DRUG

Panobinostat

Trial Locations (5)

B9 5SS

Birmingham Heartlands Hospital, Birmingham

L7 8XP

Royal Liverpool University Hospital, Liverpool

EC1A 7BE

St Bartholomew's Hospital, London

WC1E 6AG

University College London Hospitals NHS Foundation Trust, London

Unknown

Guy's Hospital, London

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Myeloma UK

OTHER

collaborator

Novartis

INDUSTRY

lead

Prof Jamie Cavenagh

OTHER

NCT02145715 - Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | Biotech Hunter | Biotech Hunter